Protara Therapeutics (TARA) Long-Term Investments (2021 - 2026)

Protara Therapeutics (TARA) has 5 years of Long-Term Investments data on file, last reported at $41.6 million in Q1 2026.

• On a quarterly basis, Long-Term Investments rose 25.6% year-over-year to $41.6 million in Q1 2026; TTM through Mar 2026 was $41.6 million, a 25.6% increase from a year earlier, with the FY2025 full-year figure at $42.3 million, changed N/A from the prior year.
• Long-Term Investments for Q1 2026 stood at $41.6 million, down from $42.3 million in the prior quarter.
• Over the last five years, Long-Term Investments for TARA reached as high as $42.3 million in Q4 2025 and fell as low as $957000.0 in Q3 2025.
• Historically, Long-Term Investments has averaged $21.8 million across 4 years, with a median of $20.6 million in 2022.
• Across the five-year window, Long-Term Investments slumped 90.63% in 2023 and gained 25.6% in 2026, its largest moves.
• Year by year, Long-Term Investments stood at $17.9 million in 2022, then plunged by 83.83% to $2.9 million in 2023, then jumped by 1363.39% to $42.3 million in 2025, then slipped by 1.64% to $41.6 million in 2026.
• Per Business Quant data, the three most recent Long-Term Investments figures were $41.6 million in Q1 2026, $42.3 million in Q4 2025, and $957000.0 in Q3 2025.